secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001193125-23-212940
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Systems receives FDA approval for HEPZATO KIT for metastatic uveal melanoma
--------------------------------------------------------------------------------

- FDA approved HEPZATO KIT (melphalan/HDS) for unresectable hepatic-dominant metastatic uveal melanoma patients.
- Phase 3 FOCUS study showed ORR 36.3%, median DoR 14 months, DCR 73.6%.
- Approval triggers Tranche A warrants for up to $34.9M additional PIPE financing within 21 days.
- Tranche B warrants for up to $24.9M exercisable upon $10M quarterly US revenue from HEPZATO.
- Commercial product expected to be available in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000119312523212940/0001193125-23-212940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000119312523212940/d324309d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-212940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer